Serum levels of cytokines and secondary messages after T-cell-depleted and non-T-cell-depleted bone marrow transplantation: Influence of conditioning and hematopoietic reconstitution

Transplantation

Volumn 62, Issue 7, 1996, Pages 947-953

  Schwaighofer, Hubert ^a   Kernan, Nancy A ^b   O'Reilly, Richard J ^b   Brankova, Juliana ^a   Nachbaur, David ^a   Herold, Manfred ^a   Eibl, Brigitte ^a   Niederwieser, Dietger ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 MICROGLOBULIN; CYCLOPHOSPHAMIDE; CYTOSTATIC AGENT; GAMMA INTERFERON; INTERLEUKIN 6; NEOPTERIN; TUMOR NECROSIS FACTOR ALPHA;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ADULT; ARTICLE; BONE MARROW TRANSPLANTATION; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; COHORT ANALYSIS; FEMALE; GRAFT VERSUS HOST REACTION; HUMAN; LYMPHOCYTE DEPLETION; MALE; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; T LYMPHOCYTE; TREATMENT PLANNING; WHOLE BODY RADIATION;

ANIMALS; BIOPTERIN; BONE MARROW CELLS; BONE MARROW PURGING; BONE MARROW TRANSPLANTATION; CYTOKINES; HEMATOPOIETIC STEM CELLS; HUMANS; LYMPHOCYTE DEPLETION; MICE; NEOPTERIN; RABBITS; SECOND MESSENGER SYSTEMS; T-LYMPHOCYTES;

EID: 0029828032     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199610150-00013     Document Type: Article

References (55)

1. Thomas ED, Storb R, Clift RA, et al. Bone-marrow transplantation. N Engl J Med 1975; 292: 1.
2. Thomas ED. Marrow transplantation for malignant diseases. J Clin Oncol 1983; 1: 517.
3. Appelbaum FR, Sullivan KM, Buckner CD, et al. Treatment of malignant lymphoma in 100 patients with chemotherapy, total body irradiation and bone marrow transplantation. J Clin Oncol 1987; 5: 1340.
4. Thomas ED, Clift RA, Fefer A, et al. Marrow transplantation for the treatment of chronic myelogenous leukemia. Ann Intern Med 1986; 104: 155.
5. De Witte T, Zwaan FE, Hermans J, et al. Allogeneic bone marrow transplantation for secondary leukemia and myelodysplastic syndrome: a survey by the leukemia working party of the European bone marrow transplantation group (EBMTG). Br J Haematol 1990; 74: 151.
6. Lucarelli G, Galimberti M, Polchi P, et al. Bone marrow transplantation in patients with thalassemia. N Engl J Med 1990; 322: 417.
7. Gluckman E, Barrett AJ, Arcese W, Devergie A, Degoulet P. Bone marrow transplantation in severe aplastic anaemia: a survey of the European group for bone marrow transplantation (EGBMT). Br J Haematol 1981; 49: 165.
8. Sullivan KM, Weiden PL, Storb R, et al. Influence of acute and chronic graft-versus-host disease on relapse and survival after bone marrow transplantation from HLA-identical siblings as treatment of acute and chronic leukemia. Blood 1989; 73: 1720.
9. Ferrara JL, Deeg HJ. Graft-versus-host disease. N Engl J Med 1991; 324: 667.
10. Hansen JA, Woodruff JM, Good RA. The graft-vs.-host reaction in man. In Safai B, Good RA, eds. Genetics, clinical features, and immunopathology: immunodermatology. New York: Plenum Publishing, 1981: 229.
11. Storb R, Prentice RL, Buckner CD, et al. Graft-versus-host disease and survival in patients with aplastic anemia treated by marrow grafts from HLA-identical siblings: beneficial effect of a protective environment. N Engl J Med 1983; 308: 302.
12. Korngold R, Sprent J. Lethal GvH-D across minor histocompatibility barriers: nature of the effector cells and role of the H2 complex. Immunol Rev 1983; 71: 5.
13. Perreault C, Decary F, Brochu S, Gyger M, Belanger R, Roy D. Minor histocompatibility antigens. Blood 1990; 76: 1269.
14. Tsoi M-S, Storb R, Dobbs S, Medill L, Thomas ED. Cell-mediated immunity to non-HLA antigens of the host by donor lymphocytes in patients with chronic graft-vs-host disease. J Immunol 1980; 125: 2258.
15. Parkman R, Rappeport J, Rosen F. Human graft versus host disease. J Invest Dermatol 1980; 74: 276.
16. Parkman R. Clonal analysis of murine graft-vs-host disease. I. Phenotypic and functional analysis of T lymphocyte clones. J Immunol 1986; 136: 3543.
17. Niederwieser D, Grassegger A, Auböck J, et al. Correlation of minor histocompatibility antigen-specific cytotoxic T lymphocytes with graft-versus-host disease status and analyses of tissue distribution of their target antigens. Blood 1993; 81: 2200.
18. Niederwieser D, Herold M, Woloszczuk W, et al. Endogenous IFN-γ during human bone marrow transplantation: analysis of serum levels of interferon and interferon-dependent secondary messages. Transplantation 1990; 50: 620.
19. Niederwieser D, Auböck J, Hajek-Rosenmayr A, Schönitzer D, Schendl D, Huber C. The role of cytokines and MHC antigens in human GvH-D: analysis of T-cell specificities and endogenous cytokine levels. Bone Marrow Transplant 1989; 4 (suppl 2): 84.
20. Piquet PF, Grau GE, Allet B, Vassalli P. Tumor necrosis factor/ cachectin is an effector of skin and gut lesions of the acute phase of graft-versus-host disease. J Exp Med 1987; 166: 1280.
21. Irschick E, Hladik F, Niederwieser D, et al. Studies on the mechanism of tolerance or graft-versus-host disease in allogeneic bone marrow recipients at the level of CTL-precursor frequencies. Blood 1992; 79: 1622.
22. Niederwieser D, Huber C, Gratwohl A, et al. Neopterin as a new biochemical marker in the clinical monitoring of bone marrow transplant recipients. Transplantation 1984; 38: 497.
23. Niederwieser D, Troppmair J, Adolph G, Margreiter R, Huber C. Role of lymphokines in the induction of graft versus host disease. Exp Hematol 1985; 13: 131.
24. Holler E, Kolb HJ, Möller A, et al. Increased serum levels of tumor-necrosis-factor alpha (TNF-alpha) precede major complications of bone marrow transplantation. Blood 1990; 75: 1011.
25. Antin JH, Ferrara JL. Cytokine dysregulation and acute graft-versus-host disease. Blood 1992; 80: 2964.
26. Dickinson AM, Sviland L, Dunn J, Carey P, Proctor SJ. Demonstration of direct involvement of cytokines in graft-versus-host reactions using an in vitro human skin explant model. Bone Marrow Transplant 1991; 7: 209.
27. Ferrara JLM. Cytokine dysregulation as a mechanism of graft versus host disease. Curr Opin Immunol 1993; 5: 794.
28. Ferrara JLM. Paradigm shift for graft-versus-host disease. Bone Marrow Transplant 1994; 14: 183.
29. McCarthy PL, Abhyankar S, Neben S, et al. Inhibition of interleukin-1 by an interleukin-1 receptor antagonist prevents graft-versus-host disease. Blood 1991; 78: 1915.
30. Hervé P, Cahn JY, Flesch M, et al. Successful graft-versus-host disease prevention without graft failure in 32 HLA-identical allogeneic bone marrow transplantations with marrow depleted of T cells by monoclonal antibodies and complement. Blood 1987; 69: 388.
31. Velardi A, Varese P, Grossi CE, et al. Cytolytic function of clonable T cells after human bone marrow transplantation. Blood 1990; 75: 1364.
32. Offit K, Burns JP, Cunningham I, et al. Cytogenetic analysis of chimerism and leukemia relapse in chronic myelogenous leukemia patients after T-cell-depleted bone marrow transplantation. Blood 1990; 75: 1346.
33. Tsoukas CD, Valentine M, Lotz M, Vaughan JH, Carson DA. The role of the T3 molecular complex in antigen recognition and subsequent activation events. Immunol Today 1984; 5: 311.
34. Filipovich AH, Vallera DA, Youle RJ, et al. Graft-versus-host disease prevention in allogeneic bone marrow transplantation from histocompatible siblings: a pilot study using immunotoxin for T cell depletion of donor bone marrow. Transplantation 1987; 44: 62.
35. Martin PJ, Hansen JA, Buckner CD, et al. Effects of in vitro depletion of T cells in HLA-identical allogeneic marrow grafts. Blood 1985; 66: 664.
36. Mitsuyasu RT, Champlin RE, Gale RP, et al. Treatment of donor bone marrow with monoclonal anti-T-cell antibody and complement for the prevention of graft-versus-host disease: a prospective, randomized, double-blind trial. Ann Intern Med 1986; 105: 20.
37. + T lymphocytes for prevention of graft-versus-host disease after allogeneic bone marrow transplantation. Blood 1990; 76: 418.
38. ™. In: Gee AP, ed. Bone marrow processing and purging: a practial guide. Boca Raton, FL: CRC Press, 1991: 201.
39. Kernan NA, Emanuel D, Castro-Malaspina H, et al. Posttransplant immune suppression with antithymocyte globulin and methylprednisolone prevents immunologically mediated graft failure (GF) following a T cell depleted marrow transplant. Blood 1989; 74 (suppl 1): 455a.
40. Speck B. Bone marrow transplantation in leukemia. Anticancer Res 1981; 1: 249.
41. Urbanski A, Schwarz T, Neuner P. Ultraviolet light induces increased circulating interleukin-6 in humans. J Invest Dermatol 1990; 94: 808.
42. Woloszczuk W, Troppmair J, Leiter E, et al. Relationship of interferon-γ and neopterin levels during stimulation with alloantigens in vivo and in vitro. Transplantation 1986; 41: 716.
43. Sachs L. Angewandte statistik. New York: Springer, 1974.
44. Huber Ch, Batchelor JR, Fuchs D, et al. Immune response associated production of neopterin: release from macrophages primarily under control of interferon gamma. J Exp Med 1984; 160: 310.
45. Schwaighofer H, Herold M, Schwarz T, et al. Serum levels of interleukin 6, interleukin 8 and C-reactive protein after human allogeneic bone marrow transplantation. Transplantation 1994; 58: 430.
46. Xun CQ, Thompson JS, Jennings CD, Brown SA, Widmer MB. Effect of total body irradiation, busulfan-cyclophosphamide, or cyclophosphamide conditioning on inflammatory cytokine release and development of acute and chronic graft-versus-host disease in H2 incompatible transplanted SCID mice. Blood 1994; 83: 2360.
47. Holler E, Kolb HJ, Mittermüller J, et al. Modulation of acute graft-versus-host disease after allogeneic bone marrow transplantation by tumor necrosis factor α (TNFα) release in the course of pretransplant conditioning: role of conditioning regimens and prophylactic application of a monoclonal antibody neutralizing human TNFα (MAK 195F). Blood 1995; 36: 1.
48. Mowat Am. Antibodies to IFN-gamma prevent immunologically mediated intestinal damage in murine graft versus host reaction. Immunology 1989; 68: 18.
49. Niederwieser D, Auböck J, Troppmair J, et al. IFN-mediated induction of MHC antigen expression on human keratinocytes and its influence on in vitro alloimmune responses. J Immunol 1988; 140: 2556.
50. Mangan KF, Mullaney MT, Barrientos TD, Kernan NA. Serum interleukin-3 levels following autologous or allogeneic bone marrow transplantation: effects of T-cell depletion, blood stem cell infusion and hematopoietic growth factor treatment. Blood 1993; 81: 1915.
51. Rameshwar P, Gascon P. Release of interleukin-1 and interleukin-6 from human monocytes by antithymocyte globulin: requirement for de novo synthesis. Blood 1992; 80: 2531.
52. Gascon P, Zoumbos NC, Scala G, Djeu JY, Moore JG, Young NS. Lymphokine abnormalities in aplastic anemia: implications for the mechanism of action of antithymocyte globulin. Blood 1985; 65: 407.
53. Reyes VE, Kumpel GR. Interferon alpha/beta synthesis during acute graft-versus-host disease. Transplantation 1987; 43: 412.
54. Pollard M, Chang LF, Srivstava KK. The role of microflora in development of graft versus host disease. Transplant Proc 1976; 8: 533.
55. de Bueger M, Bakker A, Van Rood JJ, van der Woude F, Goulmy E. Tissue distribution of human minor histocompatibility antigens: ubiquitous versus restricted tissue distribution indicates heterogeneity among human cytotoxic T lymphocyte-defined non-MHC antigens. J Immunol 1992; 149: 1788.